How does hyperfibrinogenemia lead to thrombosis?

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 1, 1997, Pages 13-17

  McDonagh, J ^a   Lee, M H ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; FIBRIN CLOT; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

EID: 0030691099     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80015-X     Document Type: Conference Paper

References (15)

1. Meade T W, North W R, Chakrabarti R R, Haines A P, Stirling Y. Population-based distribution of haemostatic variables. Br Med Bull 1977; 33: 283-288.
2. Kannel W B, Wolf P A, Castelli W P, D'Agostino R B. Fibrinogen and risk of cardiovascular disease: The Framingham study. JAMA 1987; 258: 1183-1186.
3. Deutsch D G, Mertz E T. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096.
4. Nesheim M, Fredenburgh J C, Larsen G R. The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin. J Biol Chem 1990; 265: 21541-21548.
5. 16 Cys): Biochemical and physiological characterization. Blood 1991; 78: 1744-1752.
6. Laki K. The polymerization of proteins: the action of thrombin on fibrinogen. Arch Biochem Biophys 1951; 32: 317-324.
7. Kehl M, Lottspeich F, Henschen A. Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe-Seylers Z Physiol Chem 1981; 362: 1661-1664.
8. Pozdnjakova T M, Musjalkovskaja A A, Ugarova T P, Protvin D D, Kotsjuruba V N. On the properties of fibrin monomer prepared from fibrin clot with acetic acid. Thromb Res 1979; 16: 283-288.
9. Rosenberg R D. Personal communication.
10. Nossel H L. Relative proteolysis of the fibrinogen Bβ chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981; 291: 165-167.
11. Shainoff J R, Page I H. Deposition of modified fibrinogen within the aortic intima. Atherosclerosis 1972; 16: 287-305.
12. Bini A, Fenoglio J Jr, Sobel J, Owen J, Fejgl M, Kaplan K L. Immunochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions. Blood 1987; 69: 1038-1045.
13. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Åslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
14. Rakoczi I, Wiman B, Collen D. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim Biophys Acta 1978; 540: 295-300.
15. Tran-Thang C, Kruithof E K O, Bachman F. Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots. J Clin Invest 1984; 74: 2009-2016.